Literature DB >> 31667552

[Ultra-hypofractionation in localized prostate cancer. 5-year results of the HYPO-RT-PC trial: Commentary I].

Ping Jiang1, Oliver Blanck2, Jürgen Dunst2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31667552     DOI： 10.1007/s00066-019-01535-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  14 in total

1.  Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.

Authors:  Anders Widmark; Adalsteinn Gunnlaugsson; Lars Beckman; Camilla Thellenberg-Karlsson; Morten Hoyer; Magnus Lagerlund; Jon Kindblom; Claes Ginman; Bengt Johansson; Kirsten Björnlinger; Mihajl Seke; Måns Agrup; Per Fransson; Björn Tavelin; David Norman; Björn Zackrisson; Harald Anderson; Elisabeth Kjellén; Lars Franzén; Per Nilsson
Journal:  Lancet       Date:  2019-06-18       Impact factor: 79.321

2.  Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

Authors:  Charles N Catton; Himu Lukka; Chu-Shu Gu; Jarad M Martin; Stéphane Supiot; Peter W M Chung; Glenn S Bauman; Jean-Paul Bahary; Shahida Ahmed; Patrick Cheung; Keen Hun Tai; Jackson S Wu; Matthew B Parliament; Theodoros Tsakiridis; Tom B Corbett; Colin Tang; Ian S Dayes; Padraig Warde; Tim K Craig; Jim A Julian; Mark N Levine
Journal:  J Clin Oncol       Date:  2017-03-15       Impact factor: 44.544

3.  Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.

Authors:  Shafak Aluwini; Floris Pos; Erik Schimmel; Stijn Krol; Peter Paul van der Toorn; Hanja de Jager; Wendimagegn Ghidey Alemayehu; Wilma Heemsbergen; Ben Heijmen; Luca Incrocci
Journal:  Lancet Oncol       Date:  2016-03-09       Impact factor: 41.316

4.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.

Authors:  Raymond Miralbell; Stephen A Roberts; Eduardo Zubizarreta; Jolyon H Hendry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-15       Impact factor: 7.038

5.  Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.

Authors:  Thomas Zilli; Ciro Franzese; Marta Bottero; Niccolò Giaj-Levra; Robert Förster; Daniel Zwahlen; Nikolaos Koutsouvelis; Aurelie Bertaut; Julie Blanc; Giuseppe Roberto D'agostino; Filippo Alongi; Matthias Guckenberger; Marta Scorsetti; Raymond Miralbell
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

6.  What hypofractionated protocols should be tested for prostate cancer?

Authors:  Jack F Fowler; Mark A Ritter; Rick J Chappell; David J Brenner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-15       Impact factor: 7.038

7.  Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

Authors:  W Robert Lee; James J Dignam; Mahul B Amin; Deborah W Bruner; Daniel Low; Gregory P Swanson; Amit B Shah; David P D'Souza; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; William A Hall; Paul L Nguyen; Thomas M Pisansky; Sergio L Faria; Yuhchyau Chen; Bridget F Koontz; Rebecca Paulus; Howard M Sandler
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

8.  Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer.

Authors:  Peter Hoskin; Ana Rojas; Peter Ostler; Robert Hughes; Roberto Alonzi; Gerry Lowe
Journal:  Radiother Oncol       Date:  2017-06-27       Impact factor: 6.280

9.  Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.

Authors:  Ping Jiang; Katja Krockenberger; Reinhard Vonthein; Jane Tereszczuk; Arne Schreiber; Sebastian Liebau; Stefan Huttenlocher; Detlef Imhoff; Panagiotis Balermpas; Christian Keller; Kathrin Dellas; Rene Baumann; Claus Rödel; Guido Hildebrandt; Klaus-Peter Jünemann; Alex S Merseburger; Alan Katz; Andreas Ziegler; Oliver Blanck; Jürgen Dunst
Journal:  Radiat Oncol       Date:  2017-08-18       Impact factor: 3.481

10.  Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.

Authors:  Amar U Kishan; Audrey Dang; Alan J Katz; Constantine A Mantz; Sean P Collins; Nima Aghdam; Fang-I Chu; Irving D Kaplan; Limor Appelbaum; Donald B Fuller; Robert M Meier; D Andrew Loblaw; Patrick Cheung; Huong T Pham; Narek Shaverdian; Naomi Jiang; Ye Yuan; Hilary Bagshaw; Nicolas Prionas; Mark K Buyyounouski; Daniel E Spratt; Patrick W Linson; Robert L Hong; Nicholas G Nickols; Michael L Steinberg; Patrick A Kupelian; Christopher R King
Journal:  JAMA Netw Open       Date:  2019-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.